Market Overview

UPDATE: Jefferies & Company Reiterates Underperform Rating, Raises PT on Eli Lilly & Co.

Share:
Related LLY
What If Trump Keeps Badmouthing Drug Pricing?
Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell
Early Data For Next Generation Of Imbruvica's Challengers (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Underperform rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $36.00 to $43.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Eli Lilly & Co. closed on Tuesday at $52.80.

Latest Ratings for LLY

DateFirmActionFromTo
Nov 2016Atlantic EquitiesDowngradesOverweightNeutral
Nov 2016BMO CapitalDowngradesOutperformMarket Perform
Sep 2016Goldman SachsUpgradesNeutralBuy

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

View Comments and Join the Discussion!